Pelthos Therapeutics (NYSEAMERICAN:PTHS) Upgraded at Zacks Research

Posted by George Bondi on Nov 7th, 2026

Zacks Research upgraded shares of Pelthos Therapeutics (NYSEAMERICAN:PTHS – Free Report) from a strong sell rating to a hold rating in a research report sent to investors on Wednesday morning,Zacks reports.

Several other research firms have also recently commented on PTHS. Oppenheimer decreased their price target on shares of Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a report on Friday, August 14th. Lake Street Capital dropped their price objective on shares of Pelthos Therapeutics from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, October 12th. Finally, Alliance Global Partners reiterated a “buy” rating on shares of Pelthos Therapeutics in a research report on Monday, October 26th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $52.83.

Read Our Latest Stock Report on Pelthos Therapeutics

Pelthos Therapeutics Stock Up 0.6%

Shares of PTHS stock traded up $0.06 on Wednesday, reaching $9.36. 15,709 shares of the company’s stock traded hands, compared to its average volume of 71,812. The business’s 50 day moving average price is $19.76 and its two-hundred day moving average price is $23.84. The company has a market capitalization of $35.85 million, a P/E ratio of -0.43 and a beta of 3.41. The company has a debt-to-equity ratio of 3.40, a quick ratio of 1.31 and a current ratio of 1.98. Pelthos Therapeutics has a 12-month low of $9.02 and a 12-month high of $37.40.

Pelthos Therapeutics (NYSEAMERICAN:PTHS – Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The business had revenue of $15.60 million for the quarter. Pelthos Therapeutics had a negative return on equity of 204.71% and a negative net margin of 165.24%. On average, equities analysts forecast that Pelthos Therapeutics will post -15.22 earnings per share for the current year.

Institutional Investors Weigh In On Pelthos Therapeutics

A hedge fund recently raised its stake in Pelthos Therapeutics stock. Knott David M Jr grew its position in shares of Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS – Free Report) by 9.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 21,073 shares of the company’s stock after buying an additional 1,792 shares during the quarter. Knott David M Jr owned approximately 0.63% of Pelthos Therapeutics worth $443,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 77.96% of the stock is currently owned by institutional investors.

About Pelthos Therapeutics

(Get Free Report)

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).